Intuitive Surgical Reports Strong Q4 2025 Results, Guides for Moderated 2026 Procedure Growth
summarizeSummary
Intuitive Surgical announced robust fourth-quarter 2025 financial results, with significant revenue and earnings growth, but provided 2026 guidance indicating a deceleration in da Vinci procedure growth.
check_boxKey Events
-
Strong Q4 2025 Financial Performance
Revenue for Q4 2025 increased 19% year-over-year to $2.87 billion, with non-GAAP diluted EPS rising 14.5% to $2.53.
-
Decelerated 2026 Procedure Growth Guidance
The company expects worldwide da Vinci procedure growth of 13% to 15% in 2026, a deceleration from the approximately 18% growth reported for 2025.
-
Robust Da Vinci System Placements and Installed Base Growth
Intuitive Surgical placed 532 da Vinci surgical systems in Q4 2025, including 303 da Vinci 5 systems, contributing to a 12% increase in the installed base to 11,106 systems.
-
Ion System Placements Decline
Ion endoluminal system placements decreased to 42 in Q4 2025, down from 69 in Q4 2024, despite a 24% increase in the overall Ion installed base.
auto_awesomeAnalysis
Intuitive Surgical's fourth-quarter 2025 performance was strong, marked by a 19% increase in revenue and a 14.5% rise in non-GAAP diluted EPS, driven by robust procedure volumes and da Vinci system placements. However, the company's outlook for 2026 projects da Vinci procedure growth of 13-15%, a notable deceleration from the 18% growth achieved in 2025. While still healthy, this moderated growth guidance for a key metric could influence investor sentiment, as the market often prioritizes future growth prospects for high-valuation companies.
At the time of this filing, ISRG was trading at $528.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $186.4B. The 52-week trading range was $425.00 to $616.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.